🔴 Femasys is trading 8.55% down in pre-market after investors took profits following FDA pathway approval

Femasys is trading 8.55% down in pre-market at $2.50 after investors took profits following the FDA’s modular PMA pathway approval for investigational FemBloc.

• The decision advances the regulatory process but does not authorize U.S. marketing.
• Company-specific coverage attributes the decline to profit-taking after the August 19 rally.
• Broader futures are modestly higher.